Jim Simons’s Elevation Oncology ELEV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-165,829
| Closed | -$60.9K | – | 3595 |
|
|
2025
Q2 | $60.9K | Sell |
165,829
-481,471
| -74% | -$161K | ﹤0.01% | 3367 |
|
|
2025
Q1 | $168K | Sell |
647,300
-956,009
| -60% | -$546K | ﹤0.01% | 3113 |
|
|
2024
Q4 | $902K | Sell |
1,603,309
-182,673
| -10% | -$108K | ﹤0.01% | 2553 |
|
|
2024
Q3 | $1.07M | Buy |
+1,785,982
| New | +$2.65M | ﹤0.01% | 2404 |
|
|
2024
Q1 | – | Sell |
-441,490
| Closed | -$237K | – | 3791 |
|
|
2023
Q4 | $237K | Buy |
+441,490
| New | +$234K | ﹤0.01% | 3074 |
|
|
2023
Q3 | – | Sell |
-16,800
| Closed | -$26K | – | 3759 |
|
|
2023
Q2 | $26K | Sell |
16,800
-34,700
| -67% | -$91.5K | ﹤0.01% | 3729 |
|
|
2023
Q1 | $98K | Sell |
51,500
-148,400
| -74% | -$191K | ﹤0.01% | 3496 |
|
|
2022
Q4 | $190K | Sell |
199,900
-88,757
| -31% | -$90.1K | ﹤0.01% | 3438 |
|
|
2022
Q3 | $326K | Buy |
288,657
+30,257
| +12% | +$38.1K | ﹤0.01% | 3170 |
|
|
2022
Q2 | $362K | Buy |
258,400
+233,000
| +917% | +$585K | ﹤0.01% | 3345 |
|
|
2022
Q1 | $64K | Buy |
25,400
+8,800
| +53% | +$35.3K | ﹤0.01% | 3868 |
|
|
2021
Q4 | $100K | Buy |
+16,600
| New | +$115K | ﹤0.01% | 3677 |
|
Other funds holding ELEV
Jim Simons's ELEV Position: Q3 2025 in Review
Jim Simons sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 165,829 shares — an estimated $60.9K sold.
Jim Simons first reported a position in ELEV in Q4 2021 and held it in 12 quarters. The position peaked at $1.07M in Q3 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.
- Jim Simons reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
- Jim Simons sold 165,829 Elevation Oncology shares in Q3 2025, an estimated $60.9K.
- Jim Simons first reported a position in Elevation Oncology in Q4 2021 and held it in 12 quarters.
- Jim Simons's Elevation Oncology position peaked at $1.07M in Q3 2024.
- 1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.
Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.